|
|||||
|
|
||||||
Journal of Clinical Oncology, Vol 24, No 1 (January 1), 2006: pp. 209 © 2006 American Society of Clinical Oncology. DOI: 10.1200/JCO.2005.04.1178
Prognostic Factors in Human Herpesvirus 8Related Lymphoproliferative Disorders Associated With HIV InfectionDivisions of Medical Oncology ACRO; Microbiology, Immunology and VirologyCRO; PathologyCRO, and the Epidemiology Unit, National Cancer Institute, Aviano, Italy
Department of Pathology, National Cancer Institute, Milan, Italy To the Editor: In the July 1, 2005, issue of the Journal of Clinical Oncology, Boulanger et al1 reported that a poor Eastern Cooperative Oncology Group performance status (ECOG PS) and the absence of highly active antiretroviral therapy (HAART) before a primary effusion lymphoma (PEL) diagnosis were identified as being independently associated with impaired outcome in HIV-related PEL. The prognostic value of PS has been well established in HIV-associated non-Hodgkins lymphoma (NHL),2 and the positive role of HAART in the outcome of HIV-related NHL has been recently reported.2,3 Therefore, Boulanger et al demonstrated that two of the most important clinical predictors of HIV-related NHL were applicable in HIV-PEL patients, but they did not analyze specific factors such as the Human Herpesvirus8 (HHV-8) viral load. It should be noted that in Kaposis sarcoma, the HHV-8 viral load could be a predictive marker for the development of the disease and for monitoring the patient response to therapies.4 Our group recently reported5 that HHV-8 viral load was detectable in the plasma of HIV-PEL patients before and during the chemotherapy and that HHV-8 viral load showed a significant inverse correlation with CD4 count. Moreover, we studied the HHV-8 viral load at the onset of the overall HHV-8related lymphoproliferative disorders diagnosed in The National Cancer Institute, Aviano, Italy, between April 1987 and June 2004. In all of the 25 HIV-positive patients (nine patients with Multicenter Castlemann Disease, 13 with PEL, and three with HHV-8positive solid lymphomas) diagnosed and treated in our center, the HHV-8 viral load was measurable. We observed that patients with an HHV-8 viral load greater than 40,000 copies/mL had a shorter survival time. In the univariate analysis, we identified lymphoma diagnosis (hazard ratio [HR] for death = 3.13; 95% CI, 1.12 to 8.75; P = .03), ECOG PS more than 2 (HR for death = 4.52; 95% CI, 1.59 to 12.82; P = .005) and HHV-8 viral load of more than 40,000 copies/mL diagnosis (HR for death = 3.41; 95% CI, 1.10 to 10.57; P = .03) as predictors of an increased risk of death. The multivariate analysis confirmed lymphoma diagnosis to be an independent prognostic factor associated with a higher risk of death (HR for death = 3.68; 95% CI, 1.12 to 12.10; P = .03), whereas PS and HHV-8 viral load showed a borderline significant association (HR for death = 2.78; 95% CI, 0.92 to 8.40; P = .07; HR for death = 3.73; 95% CI, 0.92 to 15.13; P = .06, respectively). Our observation suggested that PS together with HHV-8 viral load might be an important predictor of the clinical outcome of HHV-8related lymphoproliferative disorders associated with HIV infection. The lack of statistical power might be due to the small sample sizes, but the HHV-8 lymphoproliferative disorders are very rare diseases even in the HIV setting, therefore, we believe that cooperative studies, pooling several series, are needed to validate the role of the HHV-8 viral load as a prognostic marker. Authors Disclosures of Potential Conflicts of Interest The authors indicated no potential conflicts of interest. REFERENCES
1. Boulanger E, Gerard L, Gabarre J, et al: Prognostic factors and outcome of human herpesvirus 8associated primary effusion lymphoma in patients with AIDS. J Clin Oncol 23:4372-4380, 2005 2. Vaccher E, Spina M, Talamini R, et al: Improvement of systemic human immunodeficiency virus-related non-Hodgkins lymphoma outcome in the era of highly active antiretroviral therapy. Clin Infect Dis 37:1556-1564, 2003[CrossRef][Medline] 3. Antinori A, Cingolani A, Alba L, et al: Better response to chemotherapy and prolonged survival in AIDS-related lymphomas responding to highly active antiretroviral therapy. AIDS 15:1483-1491, 2001[CrossRef][Medline] 4. Boivoin G, Gaudreau A, Routy JP, Evaluation of the human herpes 8 DNA load in blood and Kaposis sarcoma skin lesions from AIDS patients on highly active antiretroviral therapy. AIDS 14:1907-1910, 2000[CrossRef][Medline] 5. Simonelli C, Tedeschi R, Gloghini A, et al: Characterization of immunologic and virologic parameters in HIV-infected patients with primary effusion lymphoma during antiblastic therapy and highly active antiretroviral therapy. Clin Infect Dis 40:1022-1027, 2005[CrossRef][Medline]
Related Reply
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||
|
Copyright © 2006 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
|